Oxygenta Pharmaceutical (524636) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
19 Aug, 2025Executive summary
Board approved unaudited financial results for the quarter ended 30 June 2025 and noted limited review by statutory auditors.
Appointments of internal, secretarial, and cost auditors for FY 2025-26 were confirmed.
Company Secretary & Compliance Officer resigned and a new appointment was made effective 14 August 2025.
Financial highlights
Total revenue for Q1 FY26 was ₹1,513.47 lakhs, up from ₹1,262.08 lakhs in Q1 FY25.
Net loss for Q1 FY26 stood at ₹610.61 lakhs, compared to a net loss of ₹136.33 lakhs in Q1 FY25.
Loss before tax for Q1 FY26 was ₹814.80 lakhs, higher than ₹281.70 lakhs in Q1 FY25.
Basic and diluted EPS for Q1 FY26 was (₹1.65), compared to (₹0.39) in Q1 FY25.
Outlook and guidance
Company is prioritizing compliance and transparency, especially regarding MSME creditor identification and bill-to-bill adjustment processes.
Latest events from Oxygenta Pharmaceutical
- Revenue up, losses down, and government credit secured in Q1 FY 2026-27.524636
Q1 26/27 - FY26 revenue rose but net loss deepened; board changes and compliance focus highlighted.524636Q4 25/26
- Revenue rose but net losses widened in Q3 FY26; compliance and creditor processes are ongoing.524636Q3 25/26
- Revenue rose modestly, but losses widened; new CFO appointed and compliance efforts ongoing.524636Q2 25/26
- Q2 FY25 revenue grew and net loss narrowed, with key statutory and compliance actions taken.524636Q2 24/25
- Q1 FY25 revenue up, net loss narrows, equity raised via share allotment; compliance issues persist.524636Q1 24/25
- Revenue surged in FY25, but losses deepened amid compliance and reporting challenges.524636Q4 24/25
- Q3 FY25 revenue surged, but losses deepened and compliance issues remain under review.524636Q3 24/25